Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Phase III KEYNOTE-204: does prior therapy impact outcomes in R/R cHL?

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, presents an exploratory analysis of the impact of a patient’s number of prior lines of therapy on outcomes in the Phase III KEYNOTE-204 trial (NCT02684292). The trial compared pembrolizumab versus brentuximab vedotin (BV) in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) patients and showed that pembrolizumab, a PD-1 inhibitor, significantly improved progression-free survival (PFS) in comparison to BV, a CD30-targeted antibody-drug conjugate. For this analysis, patients were stratified by prior lines of therapy: 1 or ≥2 therapies prior to enrollment. It was found that pembrolizumab elicited superior outcomes to BV, regardless of prior therapy status. All improvements were comparable across the trial arms, suggesting pembrolizumab may be an effective option for heavily pretreated cHL patients. An analysis of patient-reported outcomes was also conducted and showed positive results. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.